Characteristic | USA | Europe | Overall | P-value |
---|---|---|---|---|
Median CD4 count: entry (IQR) | 437 (293–600) | 420 (299–568) | 430 (294–592) | 0.6958 |
<200 cells per ml | 124 (13%) | 37 (10%) | 161 (12%) | Â |
200–499 | 294 (30%) | 132 (35%) | 426 (32%) |  |
≥500 | 560 (57%) | 203 (55%) | 763 (57%) |  |
Median HIV RNA: entry (IQR) | 581 (274–3635) | 700 (200–4740) | 594 (243–3845) | 0.1225 |
≤400 copies/ml | 424 (43%) | 142 (38%) | 566 (42%) |  |
400–2,499 | 252 (26%) | 92 (24%) | 344 (25%) |  |
2,500–10,000 | 143 (15%) | 62 (17%) | 205 (15%) |  |
>10,000 | 138 (14%) | 57 (15%) | 195 (14%) | Â |
Median CD4 count: delivery (IQR) | 480 (308–658) | 444 (320–632) | 469 (310–653) | 0.6849 |
<200 cells/ml | 103 (12%) | 26 (8%) | 129 (11%) | Â |
200–499 | 233 (27%) | 109 (34%) | 342 (29%) |  |
≥500 | 531 (61%) | 187 (58%) | 718 (60%) |  |
Median HIV RNA: delivery (IQR) | 405 (237–2638) | 200 (68–1300) | 400 (200–2300) | 0.0001 |
≤400 copies/ml | 450 (50%) | 176 (64%) | 626 (53%) |  |
400–2,499 | 220 (24%) | 49 (18%) | 269 (23%) |  |
2,500–10,000 | 115 (13%) | 36 (14%) | 151 (13%) |  |
>10,000 | 116 (13%) | 16 (6%) | 132 (11%) | Â |
Maternal ARV use | Â | Â | Â | <0.0001 |
HAART | 448 (46%) | 119 (32%) | 567 (42%) | Â |
Dual therapy | 342 (35%) | 132 (35%) | 474 (35%) | Â |
Monotherapy | 182 (19%) | 119 (32%) | 301 (22%) | Â |
No ARV | 6 (0.6%) | 2 (0.5%) | 8 (0.6%) | Â |
Timing of ARV initiation | Â | Â | Â | 0.0001 |
Pre-pregnancy | 357 (37%) | 182 (49%) | 539 (40%) | Â |
During pregnancy | 606 (63%) | 190 (51%) | 796 (60%) | Â |
Symptomatic HIV disease at entry | Â | Â | Â | 0.0194 |
Yes | 74 (8%) | 15 (4%) | 89 (7%) | Â |
No | 904 (92%) | 357 (96%) | 1261 (93%) | Â |